Cumberland Partners Ltd Buys 61,285 Shares of Pfizer Inc. $PFE

Key Points

• Cumberland Partners Ltd increased its Pfizer stake by 46.9% in the first quarter, buying 61,285 additional shares and bringing its total holdings to 191,855 shares worth about $5.39 million.
• Pfizer’s pipeline received several positive updates, including a Phase 1 safety milestone for PF-08057418, advancement of its obesity candidate PF-08653945 into early-stage trials, and FDA Priority Review for Talzenna plus Xtandi in metastatic prostate cancer.
• The company also faces mixed sentiment: shares recently traded around $24.52, analysts’ consensus remains Hold with a $28.50 target, and expanded patent litigation tied to its mRNA vaccine business is a potential overhang.

Cumberland Partners Ltd grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 46.9% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 191,855 shares of the biopharmaceutical company's stock after buying an additional 61,285 shares during the period. Cumberland Partners Ltd's holdings in Pfizer were worth $5,387,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at approximately $1,830,986,000. Morgan Stanley raised its stake in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Janus Henderson Group PLC boosted its stake in Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company's stock worth $218,817,000 after buying an additional 7,489,189 shares in the last quarter. Finally, Capital World Investors increased its holdings in Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company's stock valued at $533,704,000 after buying an additional 7,287,194 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Pfizer Price Performance

Shares of PFE stock opened at $24.52 on Friday. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm's 50 day moving average is $25.11 and its 200-day moving average is $26.16. The firm has a market capitalization of $139.78 billion, a price-to-earnings ratio of 18.72 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 EPS. Pfizer's revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 131.30%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. JPMorgan Chase & Co. decreased their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price target on the stock. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $28.50.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.